Biomarker and Diagnostic Assay Development Services for Diabetic Foot Ulcers
To address the precision medicine challenges in diagnosing diabetic foot ulcers and predicting treatment efficacy, Ace Therapeutics provides end-to-end biomarker and diagnostic method development services from discovery to validation. Our integrated services are designed to identify and validate biomarkers for predicting healing outcomes, stratifying patients, and monitoring treatment response, thereby supporting more efficient clinical trials and personalized management strategies.
Current Status and Challenges in the Diagnosis and Biomarker Development for Diabetic Foot Ulcers
The diagnosis of diabetic foot ulcers currently relies primarily on clinical assessment, supplemented by imaging studies (such as X-rays and ultrasound) and pathogen detection. However, these methods have significant limitations. Potential biomarkers identified include inflammatory cytokines (e.g., TNF-α, IL-6), matrix metalloproteinases (MMPs), growth factors (e.g., VEGF), and oxidative stress-related molecules. However, most remain in the basic research phase. There is a lack of large-scale clinically validated "gold standard" biomarkers with high specificity and sensitivity, and standardized detection protocols have yet to be established.
Fig. 1 Potential biomarkers for diagnosing diabetic foot ulcer at early stage. (Wang, Y. Q. et al., 2021)
Our Biomarker and Diagnostic Assay Development Services for Diabetic Foot
Leveraging our technical expertise and experience in diabetes, Ace Therapeutics provides global pharmaceutical companies and research institutions with comprehensive biomarker and diagnostic method development services for diabetic foot ulcers, accelerating the advancement of innovative diagnostic and therapeutic approaches.
Biomarker Discovery and Analytical Validation Services
- Biomarker Discovery: Screening potential biomarkers using multi-omics technologies including transcriptomics, proteomics, and metabolomics.
- Biomarker Validation: Validating biomarker specificity and sensitivity in large-scale cohorts through techniques such as ELISA, Western Blot, and qPCR.
- Standardization Phase: Establishing standardized procedures for biomarker detection, optimizing sample processing, experimental conditions, and data interpretation criteria.
Diagnostic Assay Development and Translation Services
- In Vitro Diagnostic Reagent Development: Develop quantitative detection products such as enzyme-linked immunosorbent assay kits and chemiluminescence detection reagents for selected biomarkers.
- Point-of-Care Testing (POCT) Technology Development: Research and develop POCT diagnostic products to meet rapid testing demands.
- Imaging-Assisted Diagnosis Development: Optimize ultrasound, infrared imaging, and other radiological data through AI algorithms to enhance diagnostic accuracy for early-stage ulcers and infections.
- Combined Diagnostic Protocol Design: Integrate multiple biomarkers or diagnostic technologies to construct multidimensional combined diagnostic models, thereby improving diagnostic efficacy.
Our Advanced Technology Platform
- Multi-omics Screening Platform
Integrating high-throughput sequencing (RNA-seq, single-cell sequencing), proteomics (LC-MS/MS), and metabolomics (GC-MS/LC-MS) technologies, this platform enables comprehensive, high-throughput biomarker screening across multiple dimensions, covering nucleic acids, proteins, metabolites, and other layers.
- Bioinformatics Analysis Platform
Provides comprehensive bioinformatics analysis, including differential expression analysis, pathway and network enrichment, machine learning-based biomarker signature development, and integrative multi-omics data modeling to prioritize candidates and assess clinical potential.
- In Vitro Diagnostics R&D Platform
We operate a standard reagent R&D laboratory, equipped with automated microplate readers, chemiluminescence analyzers, and POCT development equipment. This enables us to manage the entire workflow from reagent formulation optimization and process development to performance validation.
Ace Therapeutics is dedicated to providing professional diabetes foot biomarker and diagnostic development services for our clients through our advanced technology platforms and preclinical capabilities. If your project requires robust biomarkers for support or you are committed to developing innovative diagnostic solutions, please contact us. Our team of biomarker experts looks forward to partnering with you to advance your research and translational efforts.
Reference
- Wang, Y. Q., et al. An update on potential biomarkers for diagnosing diabetic foot ulcer at early stage. Biomedicine & Pharmacotherapy. 133 (2021): 110991.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
